Anti-pollution Effects of AP Green Tea Extracts

A Clinical Study to Evaluate the Anti-pollution Effects of AP Green Tea Extracts in Subjects With Discomforts Related to the Respiratory System by Prolonged Exposure to Particulate Matter in Air Pollution

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04340375

Enrollment

Registered

2020-04-09

Start date

2019-05-03

Completion date

2020-04-30

Last updated

2021-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Conditions Due to Unspecified External Agent

Keywords

Anti-pollution, green tea extracts

Brief summary

The objective of this clinical trial is to evaluate the anti-pollution effects of AP green tea extracts in subjects with discomforts related to the respiratory system by prolonged exposure to particulate matter in air pollution

Interventions

DIETARY_SUPPLEMENTAP green tea extracts

AP green tea extracts

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects aged 19 years or over * Subjects with discomforts related to the respiratory system by prolonged exposure to particulate matter in air pollution * Subjects who voluntarily decide to participate in this clinical study and sign the informed consent form on their own or through their representatives

Exclusion criteria

* At the screening visit, subjects who were diagnosed with acute or chronic respiratory disease and undergoing medication. * Subjects who were diagnosed with ventricular associated disease, unstable and uncontrolled chronic medical disease, or active malignant tumor and undergoing medication within 4 weeks prior to the first administration of the investigational product * Subjects who show a level of ALT/AST of 2 times or more the upper limit of normal as a result of a screening test and have acute or chronic hepatitis or known liver cirrhosis * In addition to the above, subjects who are determined to be ineligible to participate in the clinical study according to the investigator's medical opinion

Design outcomes

Primary

Measure	Time frame	Description
Pulmonary function test	4 weeks	Improvement in pulmonary function test
Respiratory health survey	4 weeks	Patients' self evaluation of COPD Assessment Test
Biomarkers	4 weeks	Blood concentration of biomarkers (Inflammatory cytokines)
Heavy metals	4 weeks	Blood concentration of heavy metals

Secondary

Measure	Time frame	Description
Bronchial assessment	4 weeks	Patients' self evaluation of Bronchiectasis Health Questionnaire

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026